Pfizer’s (PFE) “Outperform” Rating Reiterated at BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Pfizer (NYSE:PFE) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $36.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $33.00.

A number of other research analysts also recently commented on PFE. TD Cowen downgraded Pfizer from an outperform rating to a market perform rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus lowered Pfizer from a buy rating to a hold rating in a research report on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a buy rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average target price of $36.00.

Pfizer Trading Up 0.4 %

Shares of NYSE:PFE opened at $27.81 on Thursday. The company’s 50 day moving average is $26.88 and its 200 day moving average is $28.16. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer has a twelve month low of $25.20 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.23 EPS. Analysts expect that Pfizer will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter valued at $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the third quarter worth about $34,000. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Creekmur Asset Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.